Cargando…
MEK inhibition with trametinib is a successful therapy in ganglioglioma
Gangliogliomas are predominantly low-grade primary brain tumors comprised of neuronal and glial components that are found in both pediatric and young adult populations. In the majority of cases, surgical resection of these tumors is curative. However, tumor location in eloquent centers of the brain...
Autores principales: | Daniel, Eliza Baird, Ney, Douglas E, Levy, Jean M Mulcahy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523693/ https://www.ncbi.nlm.nih.gov/pubmed/32999736 |
Ejemplares similares
-
Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation
por: Miller, Katherine E., et al.
Publicado: (2021) -
Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction
por: Unsworth, Amanda J., et al.
Publicado: (2018) -
RARE-18. NF1-MUTATED TUMORS EXHIBIT INCREASED SENSITIVITY TO AUTOPHAGY INHIBITION ALONE AND IN COMBINATION WITH MEK INHIBITION
por: Baird-Daniel, Eliza, et al.
Publicado: (2021) -
Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015) -
Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis
por: Aaroe, Ashley, et al.
Publicado: (2023)